This metabolite has a PDE selectivity profile just like sildenafil and an in vitro potency for PDE5 roughly fifty% of the mum or dad drug. Plasma concentrations of this metabolite are roughly forty% of those witnessed for sildenafil, so the metabolite accounts for around 20% of sildenafil's pharmacologic consequences.Pulmonary arterial hypertension